Patents by Inventor Francis E. O'Donnell

Francis E. O'Donnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT AND PROGNOSTIC MONITORING OF PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
    Publication number: 20200375985
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Application
    Filed: May 12, 2020
    Publication date: December 3, 2020
    Inventors: NICHOLAS J. VIRCA, FRANCIS E. O'DONNELL, JR.
  • TREATMENT AND PROGNOSTIC MONITORING OF PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
    Publication number: 20190255044
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Application
    Filed: April 30, 2019
    Publication date: August 22, 2019
    Inventors: NICHOLAS J. VIRCA, FRANCIS E. O'DONNELL, JR.
  • TREATMENT AND PROGNOSTIC MONITORING OF PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
    Publication number: 20190255045
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Application
    Filed: April 30, 2019
    Publication date: August 22, 2019
    Inventors: NICHOLAS J. VIRCA, FRANCIS E. O'DONNELL, JR.
  • Treatment of prostate cancer using hedgehog pathway inhibitors
    Patent number: 10363252
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: July 30, 2019
    Assignee: HEDGEPATH PHARMACEUTICALS, INC.
    Inventors: Nicholas J. Virca, Francis E. O'Donnell, Jr.
  • Treatment of lung cancer using hedgehog pathway inhibitors
    Patent number: 10328072
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: June 25, 2019
    Assignee: HEDGEPATH PHARMACEUTICALS, INC.
    Inventors: Nicholas J. Virca, Francis E. O'Donnell, Jr.
  • TREATMENT AND PROGNOSTIC MONITORING OF CANCEROUS PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
    Publication number: 20180243295
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Application
    Filed: April 30, 2018
    Publication date: August 30, 2018
    Inventors: NICHOLAS J. VIRCA, FRANCIS E. O'DONNELL, Jr.
  • TREATMENT AND PROGNOSTIC MONITORING OF NON-CANCEROUS PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
    Publication number: 20180243296
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Application
    Filed: April 30, 2018
    Publication date: August 30, 2018
    Inventors: NICHOLAS J. VIRCA, FRANCIS E. O'DONNELL, JR.
  • Treatment and prognostic monitoring of non-cancerous proliferation disorders using hedgehog pathway inhibitors
    Patent number: 9968600
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: May 15, 2018
    Assignee: HEDGEPATH PHARMACEUTICALS, INC.
    Inventors: Nicholas J. Virca, Francis E. O'Donnell, Jr.
  • Treatment and prognostic monitoring of cancerous proliferation disorders using Hedgehog pathway inhibitors
    Patent number: 9962381
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: May 8, 2018
    Assignee: HEDGEPATH PHARMACEUTICALS, INC.
    Inventors: Nicholas J. Virca, Francis E. O'Donnell, Jr.
  • TREATMENT AND PROGNOSTIC MONITORING OF CANCEROUS PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
    Publication number: 20170136011
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Application
    Filed: January 31, 2017
    Publication date: May 18, 2017
    Inventors: NICHOLAS J. VIRCA, FRANCIS E. O'DONNELL, JR.
  • TREATMENT AND PROGNOSTIC MONITORING OF NON-CANCEROUS PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
    Publication number: 20170136012
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Application
    Filed: January 31, 2017
    Publication date: May 18, 2017
    Inventors: NICHOLAS J. VIRCA, FRANCIS E. O'DONNELL, JR.
  • TREATMENT AND PROGNOSTIC MONITORING OF PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
    Publication number: 20160074393
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Application
    Filed: November 20, 2015
    Publication date: March 17, 2016
    Inventors: Nicholas J. VIRCA, Francis E. O'DONNELL, JR.
  • TREATMENT AND PROGNOSTIC MONITORING OF PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
    Publication number: 20160074392
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Application
    Filed: November 20, 2015
    Publication date: March 17, 2016
    Inventors: NICHOLAS J. VIRCA, FRANCIS E. O'DONNELL, JR.
  • Method of identifying patients not suitable for high-dose cyclophosphamide treatment
    Patent number: 9279803
    Abstract: The present invention provides methods of identifying subjects that are suitable and not suitable for high-dose cyclophosphamide treatment.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: March 8, 2016
    Assignees: The Johns Hopkins University, Accentia Biopharmaceuticals, Inc.
    Inventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, Jr., Susan Bonitz, Adam Kaplin, Carlos Santos
  • Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
    Patent number: 9192609
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: November 24, 2015
    Assignee: HEDGEPATH PHARMACEUTICALS, INC.
    Inventors: Nicholas J. Virca, Francis E. O'Donnell, Jr.
  • Formulations, devices and methods for treating and preventing mucositis
    Patent number: 8940319
    Abstract: The present invention is directed to compositions, devices, and methods for non-irritatively treating and preventing mucositis, such as chronic rhinosinusitis (CRS). Some aspects of the invention concern compositions comprising or consisting essentially of sodium phosphate buffer (e.g., sodium phosphate dibasic and sodium phosphate monobasic) and calcium carbonate; mucoadministration devices and kits containing such compositions; and methods for treating or preventing mucositis conditions such as CRS, comprising mucoadministering a composition of the invention to a subject in need thereof.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: January 27, 2015
    Assignee: Accentia Biopharmceuticals, Inc.
    Inventors: Francis E. O'Donnell, Angelos M. Stergiou
  • TREATMENT AND PROGNOSTIC MONITORING OF PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
    Publication number: 20140315920
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Application
    Filed: February 5, 2014
    Publication date: October 23, 2014
    Applicant: HEDGEPATH, LLC.
    Inventors: NICHOLAS J. VIRCA, FRANCIS E. O'DONNELL, JR.
  • Cyclophosphamide in combination with anti-idiotypic vaccines
    Patent number: 8673321
    Abstract: The present invention relates to methods of treating a cancer and in particular, a B-cell derived cancer, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as, for example, an autologous idiotypic vaccine and monoclonal antibodies that selectively bind B-cell specific antigens.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: March 18, 2014
    Assignees: The Johns Hopkins University, Accentia Biopharmaceuticals, Inc.
    Inventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, Jr., Susan Bonitz, Carlos Santos
  • FORMULATIONS, DEVICES AND METHODS FOR TREATING AND PREVENTING MUCOSITIS
    Publication number: 20120237618
    Abstract: The present invention is directed to compositions, devices, and methods for non-irritatively treating and preventing mucositis, such as chronic rhinosinusitis (CRS). Some aspects of the invention concern compositions comprising or consisting essentially of sodium phosphate buffer (e.g., sodium phosphate dibasic and sodium phosphate monobasic) and calcium carbonate; mucoadministration devices and kits containing such compositions; and methods for treating or preventing mucositis conditions such as CRS, comprising mucoadministering a composition of the invention to a subject in need thereof.
    Type: Application
    Filed: June 1, 2012
    Publication date: September 20, 2012
    Applicant: ACCENTIA BIOPHARMACEUTICALS, INC.
    Inventors: FRANCIS E. O'DONNELL, JR., ANGELOS M. STERGIOU
  • Formulations, devices and methods for treating and preventing mucositis
    Patent number: 8211460
    Abstract: The present invention is directed to compositions, devices, and methods for non-irritatively treating and preventing mucositis, such as chronic rhinosinusitis (CRS). Some aspects of the invention concern compositions comprising or consisting essentially of sodium phosphate buffer (e.g., sodium phosphate dibasic and sodium phosphate monobasic) and calcium carbonate; mucoadministration devices and kits containing such compositions; and methods for treating or preventing mucositis conditions such as CRS, comprising mucoadministering a composition of the invention to a subject in need thereof.
    Type: Grant
    Filed: August 3, 2009
    Date of Patent: July 3, 2012
    Assignee: Accentia Biopharmaceuticals, Inc.
    Inventors: Francis E. O'Donnell, Jr., Angelos M. Stergiou